Premium
Treatment and outcomes in classic Hodgkin lymphoma post‐transplant lymphoproliferative disorder in children
Author(s) -
Twist Clare J.,
Hiniker Susan M.,
Gratzinger Dita,
Gutkin Paulina M.,
Merriott David J.,
Iagaru Andrei,
Link Michael P.,
Donaldson Sarah S.
Publication year - 2019
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.27803
Subject(s) - medicine , lymphoma , lymphoproliferative disorders , hodgkin lymphoma , chemotherapy , radiation therapy , post transplant lymphoproliferative disorder , pediatrics , retrospective cohort study , oncology , rituximab
Classic Hodgkin lymphoma post‐transplant lymphoproliferative disorder (HL‐PTLD) has been rarely reported in children, with limited data available to guide treatment decisions. We report a retrospective review of five children diagnosed with classic HL‐PTLD following solid organ transplant between 2007 and 2013 at Stanford University. Patients were treated with Stanford V chemotherapy and involved field radiation therapy. With a median follow‐up of 7.2 years (range, 4.7–10.5 years) since diagnosis, all patients remain in remission from HL‐PTLD and free from graft failure. In this series, combined modality therapy with risk‐adapted chemotherapy and radiation therapy was a successful strategy for the treatment of classic HL‐PTLD.